develop invasive fungal infections. 1 4 The diagnosis of fungal infections is particularly difficult in immunocompromised
|
|
- Nancy Holmes
- 5 years ago
- Views:
Transcription
1 Bone Marrow Transplantation, (1997) 20, Stockton Press All rights reserved /97 $12.00 Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies J Mehta 1, S Kelsey 2, P Chu 3, R Powles 1, D Hazel 2, U Riley 1, C Evans 1, A Newland 2, J Treleaven 1 and S Singhal 1 1 Royal Marsden Hospital, Surrey; 2 Royal London Hospital, London; and 3 Royal Liverpool University Hospital, Liverpool, UK Summary: develop invasive fungal infections. 1 4 The diagnosis of fungal infections is particularly difficult in immunocompromised Sixty-four adult patients (median age 43) with hematologic patients, and most patients are treated presumptively. malignancies who were immunocompromised after Early institution of anti-fungal therapy is associated with allogeneic (n = 23) or autologous (n = 9) blood/marrow better outcome, and withholding therapy until a definitive transplantation, or chemotherapy (n = 32) received 68 diagnosis is made results in dissemination of the infection courses of amphotericin B lipid complex (ABLC, with a high mortality. 4 Abelcet) at the daily dose of 5 mg/kg for presumed Amphotericin B is the primary treatment for systemic (n = 52) or proven (n = 16) fungal infection. The major fungal infections in immunocompromised patients because indications for ABLC were failure of previous antifun- of its broad spectrum of activity. 5,6 However, its use is gal therapy and/or renal dysfunction. Fifty-three treatment limited by a variety of adverse effects including severe courses in 49 patients comprising 4 58 doses systemic reactions such as fever, rigors, phlebitis and (median 10) were considered evaluable. Fourteen bronchospasm. 6 The major problem with amphotericin is courses administered for confirmed infections resulted its dose-related nephrotoxicity which compromises its efficacy in nine complete and one partial responses, and four in treating systemic fungal infections and restricts its failures (71% response). Thirty-nine empiric courses prophylactic use. 7 Drug-induced renal dysfunction is a resulted in 18 complete and six partial responses, and major concern after blood or marrow transplantation 14 failures (64% response). The overall response rate (BMT), 8,9 where the use of a less nephrotoxic formulation was 66%. Five of seven evaluable patients with aspergillus of amphotericin would be particularly attractive. 10 pneumonia responded. Response rates were compa- A number of lipid-based formulations of amphotericin rable for chemotherapy, autograft and allograft recipients. have been developed to improve the tissue distribution of The change in serum creatinine from the beginning amphotericin and to reduce the toxicity associated with to the end of therapy was 284 to +277 mol/l (median conventional amphotericin. 10 Amphotericin B lipid com- +24). The creatinine doubled during seven evaluable plex (ABLC) is derived from a liposomal formulation of courses of therapy, five of which were associated with amphotericin B consisting of dimyristoyl-phosphatidyl- concomitant nephrotoxic therapy. Nephrotoxicity was choline and dimyristoyl-phosphatidylglycerol in a 7:3 comparable for transplant and chemotherapy patients. molar ratio. Unlike the original liposomal formulation, Renal dysfunction necessitated discontinuation of ABLC has a ribbon-like appearance. 10 ABLC in only four patients. These data suggest that Here, we report our experience with the use of ABLC ABLC is effective in presumed or confirmed fungal for the treatment of suspected or proven fungal sepsis in infections in immunocompromised patients after transplantation immunocompromised patients with hematologic malig- or chemotherapy. nancies undergoing BMT or receiving chemotherapy. Keywords: Abelcet; amphotericin B, amphotericin B lipid complex; aspergillosis; candidiasis; fungal infection Patients and methods Approximately one-third of neutropenic patients who Between May 1994 and October 1995, 64 adult patients remain persistently febrile on standard antibiotic therapy with hematologic malignancies who were immunocompromised or neutropenic as a result of chemotherapy or BMT received ABLC (Abelcet, The Liposome Company, Prince- Correspondence: Dr J Mehta, Division of Hematology/Oncology, Slot 508, ton, NJ, USA) at the Royal Marsden Hospital (n = 46), the University of Arkansas for Medical Sciences, 4301 West Markham, Little Royal London Hospital (n = 10), or the Royal Liverpool Rock, Arkansas 72212, USA University Hospital (n = 8). All patients had received some Presented at the 37th Annual Meeting of the American Society of Hema- tology, Seattle, December 1995 Received 4 November 1996; accepted 11 March 1997 form of topical anti-fungal prophylaxis (nystatin with or without amphotericin lozenges).
2 40 Diagnosis of fungal infections ABLC in immunocompromised patients Refractory fever not responding to at least 72 h of broad- spectrum combination antibiotic therapy and/or coarse pulmonary infiltrates with negative cultures from all appropri- ate sites were considered evidence of a presumptive fungal infection. Patients with coarse pulmonary infiltrates usually received therapy directed against atypical bacteria, Pneumocystis carinii, and cytomegalovirus in varying combinations depending upon the clinical situation in addition to anti-fungal therapy. Confirmed fungal infections were diagnosed on the basis of positive cultures or histologic results. Growth of a Candida species organism from stool or throat in the absence of symptoms was not considered an evidence of candidiasis. ABLC (usually from the morning of the day ABLC was started) was considered the baseline creatinine, and the first creatinine level after the last dose of ABLC (usually from the morning of the day after ABLC was stopped) was considered the final creatinine. The effect of the drug on the kidneys was expressed as the difference in these two values. Concomitant therapy with other nephrotoxic drugs (cyclosporine, ganciclovir, foscarnet, high-dose intravenous acyclovir, vancomycin and aminoglycosides) was specifi- cally recorded. Data were collected using a standard proforma at the time of treatment or retrospectively from the notes (Royal London Hospital and Royal Liverpool University Hospital) and the prospective Leukaemia/Myeloma Research Data- bases of the Royal Marsden Hospital. 12,13 ABLC therapy The indications for ABLC therapy 11 were as follows: (1) proven invasive fungal infection; (2) strong clinicoradiologic picture of fungal infection in patients who were neu- tropenic and expected to remain neutropenic for the next few days, and who were on other nephrotoxic drugs; (3) refractory fever with compromised renal function ( 50% elevation of creatinine from baseline) and/or high intravenous potassium supplementation requirements ( 120 meq per day); (4) failure to respond to conventional amphotericin or fluconazole (persistent fever for 3 days after introduction of antifungal therapy in presumed infections, or failure to show any clinical, radiologic or microbiologic sign of improvement for 3 days in confirmed infections); or (5) intolerance of conventional amphotericin (severe systemic reactions despite adequate premedication). ABLC was administered intravenously at a daily dose of 5 mg/kg. Premedication with corticosteroids or antihista- mine agents was not usually employed. Treatment courses comprising at least four doses of ABLC were considered evaluable for efficacy as well as toxicity. Treatment courses comprising less than four doses of ABLC were not considered evaluable for efficacy, but were evaluated for nephrotoxicity and systemic adverse reactions. Results Table 1 shows the baseline characteristics of the 64 patients. A total of 68 treatment courses was administered (four patients received two treatment courses each). The dose was 5 mg/kg during 67 courses, and 3 mg/kg during one. The drug was administered daily during 63 courses, and daily followed by every alternate day during five. Sixteen of the treatment courses were for microbiologically confirmed fungal infections (six in BMT recipients), and 52 for presumptive infections (28 in BMT recipients). Ten of the confirmed infections were due to Aspergillus spp. (microscopic/culture examination of sputum, bron- choalveolar lavage or sinus drainage), five due to Candida spp., and one due to Cryptococcus neoformans (Table 2). Hepatosplenic candidiasis was diagnosed in one patient on the basis of fever, neutrophilia, liver function abnormalities, and a characteristic appearance of the liver and the spleen on ultrasonography. However, a liver biopsy was not per- formed. This patient has been included in the presumptive infections group. The indications for anti-fungal therapy in patients with- Table 1 Patient characteristics Evaluation of response Number of patients 64 In patients with confirmed infections, complete response Sex was defined as clearance of all clinical, radiologic, and lab- Male 47 oratory evidence of disease. Partial response was defined Female 17 Median age (range) years 43 (17 68) as clearance of all clinical evidence and 50% clearance Diagnosis of the radiologic evidence of disease with or without Acute leukemia 35 microbiologic response. Failure was defined as persistence Chronic leukemia 7 or progression of signs or symptoms on therapy, or 50% Lymphoma 7 resolution of the radiologic findings with persistently posi- Multiple myeloma 9 Other 6 tive culture. In patients with presumed infections, lack of Number of courses of therapy 68 resolution of fever within 72 h or 50% clearance of lung Therapeutic intervention infiltrates was considered failure, 50% clearance of pul- Allogeneic bone marrow transplantation 24 monary infiltrates partial response, and complete resolution Autologous blood or marrow transplantation 10 Chemotherapy 34 of infiltrates or defervescence of fever complete response. Indication for anti-fungal therapy (%) Presumed fungal sepsis 52 (76) Nephrotoxicity Proven fungal infection 16 (24) Median neutrophil count at the initiation of /l (0 12.2) All patients were monitored with daily serum creatinine ABLC (range) measurements. The last creatinine level prior to starting
3 ABLC in immunocompromised patients Table 2 Confirmed fungal infections and response pneumonia. However, on retrospective review, the creatinine was found to have decreased after an initial rise while Total No. Evaluable Complete Partial Failure the patient was still on ABLC. The incidence of systemic response response adverse reactions was similar for chemotherapy and transplant patients. Aspergillus a 1 2 pneumonia Candidemia Aspergillus Response in confirmed infections sinusitis Nine complete responses were seen, including two patients with pulmonary aspergillosis in whom there was over 90% candidiasis clearance of the lung infiltrates with complete microbio- Cryptococcal meningitis logic resolution and resolution of the symptoms after 4 weeks of ABLC. In these two patients, complete clearance Total of the lung infiltrates on CT scanning occurred over the Oropharyngeal One patient with the characteristic clinical and radiologic picture of hepa- ensuing several weeks with intraconazole maintenance. tosplenic candidiasis but in whom microbiologic documentation was not Another patient with pulmonary aspergillosis in whom 7 available has been included in the presumptive therapy group. The syn- days of ABLC resulted in over 50% clearance of lung infildrome resolved completely on ABLC (see text). a trates and resolution of all clinical symptoms was classified Two patients were switched to prolonged oral itraconazole when all clinias a partial responder because nephrotoxicity necessitated cal symptoms had resolved, repeat sputum cultures were negative, and the radiologic changes had improved by 90 95%. discontinuation of ABLC. Four patients did not respond, and the overall response rate was 71% (10 of 14). Three of the four non-responders out confirmed fungal infections were: refractory fever died as a result of the fungal infection, and one died (n = 17), pulmonary infiltrates (n = 16), combination of the because of complications of the underlying disease. Four two (n = 17), oral mucositis (n = 1), and a characteristic cli- of six transplant recipients, including three of four with nicoradiologic picture of hepatosplenic candidiasis (n = 1). Aspergillus pneumonia responded. The indications for the use of ABLC (rather than conven- Table 2 shows response by site of infection and species. tional amphotericin or fluconazole/itraconazole) are shown All five patients with candidiasis responded, while the in Table 3. response rate in pulmonary aspergillosis was 71% (five of Fifty-three courses comprising at least four doses (4 58 seven). None of the evaluable patients with aspergillosis doses, median 10) were considered evaluable for efficacy, had received conventional amphotericin prior to receiving whereas 15 courses of one to three doses were considered ABLC, but all the patients with candidiasis had received non-evaluable for efficacy. Fourteen of the evaluable conventional amphotericin for 3 7 days prior to starting courses were for confirmed fungal infections (six in BMT ABLC. recipients), and 39 for presumed infections (23 in BMT Three of the seven evaluable patients with pulmonary recipients). aspergillosis had neutrophil counts of /l at the onset of therapy; partial response was seen in one, and the Non-evaluable courses drug was changed to liposomal amphotericin (AmBisome, NexStar, Boulder, CO, USA) in the other two due to Five patients developed systemic reactions to ABLC (fever nephrotoxicity after 4 and 7 days of therapy. All four with or without rigor and sweating) on the first day, and did not receive a second dose of the drug. None of these had received any premedication for ABLC administration. Eight patients (including one with Aspergillus pneumonia) died as a result of the underlying malignancy or complications of therapy after receiving one to three doses of ABLC. The drug was discontinued after two doses in a patient who was being treated empirically and whose gen- eral clinical condition improved significantly. The drug was discontinued due to an apparent elevation in serum creati- nine after three doses in another patient with Aspergillus patients with neutrophil counts of /l at the onset of treatment responded. Response in presumptive infections Nineteen of the 39 empiric courses resulted in complete response (resolution of fever or pulmonary infiltrates, or complete resolution of the clinicoradiologic picture of hepatosplenic candidiasis), and six in partial response (incomplete resolution of pulmonary infiltrates). Fourteen courses failed, resulting in a 63% response rate (24 of 38). 41 Table 3 Indication for ABLC Overall response The overall response rate was 66% (35 of 53), and was Failure of previous amphotericin or fluconazole therapy 28 comparable for chemotherapy (18 of 30; 60%), autograft Pre-existing renal dysfunction 16 (7 of 9; 77%) and allograft (10 of 14; 71%) recipients. Sev- Combination of the above factors 12 Intolerance of conventional amphotericin 6 enteen of 20 courses administered with initial neutrophil Previous invasive fungal infection 4 counts of more than /l resulted in a response com- Unknown 2 pared with 18 of 33 courses with neutrophils less than /l (P = 0.069, Fisher s exact test).
4 42 ABLC in immunocompromised patients Among the 40 patients who had failed prior anti-fungal therapy with fluconazole or conventional amphotericin, four were not evaluable, 12 did not respond, and 24 responded (67% of 36 evaluable patients). Table 4 Change in renal function as a result of ABLC therapy Group Change in creatinine % change ( mol/l) median and median and range range Systemic adverse reactions Chemotherapy Seven patients developed febrile reactions to ABLC. None 284 to to +212 Autograft of them had been premedicated for ABLC administration. 60 to to +141 The drug was stopped in five patients after a single dose, Allograft to to +270 but was continued uneventfully in two after premedication P (chemotherapy vs with steroids. Subsequently, all patients with a previous his- autograft) tory of reactions to conventional amphotericin received preallograft) P (autograft vs medication prior to ABLC administration and no reactions P (allograft vs were seen. Another patient developed tachycardia and chemotherapy tachypnea on the 8th day of therapy resulting in the discon- On cyclosporine tinuation of ABLC. 64 to to +270 Not on cyclosporine Renal function 284 to to +212 P On other nephrotoxic The baseline serum creatinine was mol/l (median drugs a 284 to to ). The change in serum creatinine over all the treatment Not on other courses was 284 to +277 mol/l (median +24), and over nephrotoxic drugs 217 to to +212 P the 53 evaluable courses, 110 to +277 mol/l (median Baseline creatinine ). The creatinine doubled over seven evaluable courses to to +270 of therapy, during five of which patients were receiving Baseline creatinine concomitant therapy with one to four other nephrotoxic to to +256 agents (cyclosporine, aminoglycosides, vancomycin, highdose P intravenous acyclovir, ganciclovir or foscarnet). Nephrotoxicity necessitated discontinuation of ABLC in a Including cyclosporine. only three patients. The creatinine increased by 50% of the baseline value in 10 of 24 allograft, two of 10 autograft, amphotericin in 178 patients with invasive aspergillosis. Of and seven of 34 chemotherapy recipients (P = 0.18, 2 test). the 111 patients considered evaluable for response, 40% of As Table 4 shows, there was a trend towards patients on the ABLC-treated patients responded compared with 23% cyclosporine and those with initially normal creatinine to of those treated with conventional amphotericin develop more elevated creatinine. (P = 0.002). Despite the high concentrations in the liver and the lungs, concentrations in the kidneys are comparable to conventional Discussion amphotericin and plasma levels are consistently lower, 16 which may explain the kidney-sparing effect of Our data suggest that ABLC is effective for the treatment ABLC. of microbiologically proven or clinically suspected fungal We found that although serum creatinine levels tended infections in immunocompromised patients with hematologic to increase, significant elevations (to more than double the malignancies including patients failing previous ther- baseline) were seen in less than 15% of the patients, most apy with fluconazole or conventional amphotericin. It may of whom were receiving other nephrotoxic agents as well. thus provide a useful first-line or salvage alternative to con- More importantly, renal toxicity resulted in discontinuation ventional amphotericin in the setting of BMT or chemotherapy. of the drug in only four of 68 cases (6%). As Table 4 As observed by others, 14,15 our data show that shows, no factor was consistently associated with elevation nephrotoxicity is not a major problem with ABLC. in creatinine levels. The pharmacokinetic properties of ABLC can explain its Because of their high cost, drugs such as ABLC are usually favorable toxicity and efficacy profile. The results of tissue used when the patient s clinical situation is poor, somefavorable distribution studies with ABLC in animals have shown a times when significant multi-organ dysfunction is present. dose-dependent increase in mean amphotericin concentrations In some of these cases, failure of therapy is due to death in the liver, spleen and lung. 16 The liver, spleen resulting from causes other than the fungal infection. It is and lungs are often the sites of deep fungal infections such possible that the use of ABLC earlier on, in the period of as candidiasis and aspergillosis. Targeted drug delivery to febrile neutropenia or after confirmed fungal infection, may these sites could potentially be beneficial for local eradication allow a higher proportion of patients to be treated success- of the infection. This could account for the high fully. response rates in invasive fungal infections, as seen with We conclude that ABLC is effective for presumed or pulmonary aspergillosis in our study. Hiemenz et al 17 confirmed fungal infections in high-risk immunocompromised reported a historical comparison of ABLC and conventional patients including those who have failed treatment
5 ABLC in immunocompromised patients with conventional amphotericin or fluconazole. Nephrotoxwith ing autologous bone marrow transplantation in adult patients icity requiring discontinuation of ABLC is rare. The drug acute leukemia. Acta Oncol 1996; 35: requires further evaluation in the management of fungal 10 Mehta J. Do variations in molecular structures affect the cliniinfections, especially at earlier stages of infection when the cal efficacy and safety of lipid-based amphotericin B prep- arations? Leuk Res 1997; 21: patient s general condition is better. 11 Franklin IM, Mehta J, Root T. The use of amphotericin B lipid complex/ablc (Ablcet) as an alternative to conventional References amphotericin B. J Antimicrob Chemother 1997; 39: Powles R, Milan S, Horton C et al. A prospective haematooncology 1 Goodrich JM, Reed EC, Mori M et al. Clinical features and patient database: structure and description. Bone analysis of risk factors for invasive candidal infection after Marrow Transplant 1996; 17 (Suppl. 1): S140. marrow transplantation. J Infect Dis 1991; 164: Powles R, Milan S, Horton C et al. A prospective haemato- 2 Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with oncology patient database for use in routine care and clinical hematologic malignancies: a reappraisal. Blood 1995; 86: research. Bone Marrow Transplant 1996; 17 (Suppl. 1): S Walsh TJ, Hiemenz JW, Seibel N, Anaissie EJ. Amphotericin 3 Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non- B lipid complex in the treatment of 228 cases of invasive Candida fungal infections following bone marrow transplan- mycosis. Proceedings of the 34th Interscience Conference on tation. Medicine Baltimore 1993; 72: Antimicrobial Agents and Chemotherapy, October 1994, 4 Pizzo PA. Management of fever in patients with cancer and Orlando, p 247 (Abstr. M69). treatment-induced neutropenia. New Engl J Med 1993; 328: 15 Anaissie EJ, White M, Uzun O et al. Amphotericin B lipid complex (ABLC) vs amphotericin B (AMB) for treatment of 5 Bowler WA, Oldfield EC. New approaches to amphotericin B hematogenous and invasive candidiasis: a prospective, ranadministration. Infect Med 1992; 9: domized, multicenter trial. Proceedings of the 35th Interscience 6 Warnock DW. Amphotericin B: an introduction. J Antimicrob Conference on Antimicrobial Agents and Chemo- Chemother 1991; 28 (Suppl. B): therapy, September 1995, San Francisco, p 330 (Abstr. 7 Bodey GP, Anaissie EJ, Elting LS et al. Antifungal prophylaxis LM21). during remission induction therapy for acute leukemia 16 Janoff AS, Perkins WR, Saleton SL, Swenson CE. Ampho- fluconazole versus intravenous amphotericin B. Cancer 1994; tericin B lipid complex (ABLC): a molecular rationale for the 73: attenuation of amphotericin B related toxicities. J Liposome 8 Bearman SI, Appelbaum FR, Back A et al. Regimen-related Res 1993; 3: toxicity and early post-transplant survival in patients undergo- 17 Hiemenz JW, Lister J, Anaissie EJ et al. Emergency-use ing marrow transplantation for lymphoma. J Clin Oncol 1989; amphotericin B lipid complex (ABLC) in the treatment of 7: patients with aspergillosis: historical control comparison with 9 Glynne P, Powles R, Steele J et al. Renal dysfunction follow- amphotericin B. Blood 1995; 86: (Suppl. 1): 849a. 43
Cigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationamphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More informationAmphotericin B Lipid Complex (Abelcet ) 05/06
Amphotericin B Lipid Complex (Abelcet ) Structure and Activity AMB : DMPC : DMPG lipid complex, 10:7:3 mol:mol ribbon-like lipid structures, 1.6-11 µm in diameter binds to ergosterol disturbance of cell
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationTREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY
TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS Part I: EMPIRICAL THERAPY CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES NIJMEGEN, THE NETHERLANDS n = 328 BACTERIAL INFECTION FUNGAL INFECTION 7% 36%
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationNeutropenic Sepsis Guideline
Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationGJ Timmers 1, S Zweegman 1, AM Simoons-Smit 2, AC van Loenen 3, D Touw 3 and PC Huijgens 1. Summary:
(2000) 25, 879 884 2000 Macmillan Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nature.com/bmt Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationInvasive fungal infections have become an increasing
A Multicenter, Randomized Trial of Fluconazole versus Amphotericin B for Empiric Antifungal Therapy of Febrile Neutropenic Patients with Cancer* Drew J. Winston, MD, James W. Hathorn, MD, Mindy G. Schuster,
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationEmpiric use of systemic antibiotics has reduced the
A Randomized Comparison of with as Empiric Anti-Fungal Agents in Cancer Patients with Prolonged Fever and Neutropenia Imtiaz A. Malik, MD, Imran Moid, MBBS, Zeba Aziz, MD, Shireen Khan, MBBS, Mohammad
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationEMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationDepartment of Pediatric Hematology/Oncology, University Children s Hospital Tübingen, Hoppe-Seyler-Strß 1, Tübingen, Germany 2
Case Reports in Transplantation Volume 2012, Article ID 672923, 4 pages doi:10.1155/2012/672923 Case Report Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem
More informationESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel
CASE PRESENTATION ECCMID clinical grand round May 2014 Anat Stern, MD Rambam medical center Haifa, Israel An 18 years old Female, from Ukraine, diagnosed with acute lymphoblastic leukemia (ALL) in 2003.
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationAmphotericin B or Ketoconazole Therapy of Fungal Infections in Neutropenic Cancer Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1987, p. 11-15 0066-4804/87/010011-05$02.00/0 Copyright 1987, American Society for Microbiology Vol. 31, No. 1 or Therapy of Fungal Infections in Neutropenic
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationAntifungal Therapy in Leukemia Patients
Antifungal Therapy in Leukemia Patients UPDATE ECIL 4, 6 September 2011 Raoul Herbrecht, Ursula Flückiger, Bertrand Gachot, Patricia Ribaud, Anne Thiebaut, Catherine Cordonnier UPDATE ECIL 4, 2011 UPDATE
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationEvaluation of hypokalemia and potassium supplementation during administration of liposomal amphotericin B
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 941-946, 2014 Evaluation of hypokalemia and potassium supplementation during administration of liposomal amphotericin B EISEKI USAMI 1, MICHIO KIMURA 1, TETSUFUMI
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationCondition First line Alternative Comments Candidemia Nonneutropenic adults
Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationNo Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationCommon Fungi. Catherine Diamond MD MPH
Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold
More informationHigh risk neutropenic patient (anticipated duration > 10 days) Send blood twice weekly for Beta -D Glucan Galactomanan Aspergillus PCR
DERBY TEACHING HOSPITALS NHS FOUNDATION TRUST Prophylaxis, diagnosis and treatment of invasive fungal infections in oncology/haematology patients with prolonged neutropenia. High risk neutropenic patient
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationESCMID Online Lecture Library. by author
The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated
More informationECMM Excellence Centers Quality Audit
ECMM Excellence Centers Quality Audit Person in charge: Department: Head of Department: Laboratory is accredited according to ISO 15189 (Medical Laboratories Requirements for quality and competence) Inspected
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationHAEMATOLOGY ANTIFUNGAL POLICY
HAEMATOLOGY ANTIFUNGAL POLICY PROPHYLAXIS Primary Prophylaxis Patient Group Patients receiving intensive remissioninduction chemotherapy for Acute Leukaemia (excluding patients receiving vinca alkaloids)
More informationObjec&ves. Clinical Presenta&on
Michelle A. Barron, MD Associate Professor of Medicine Division of Infectious Diseases University of Colorado Denver Objec&ves Determine who is at risk for invasive candidiasis. Understand whether prophylaxis
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationPAGL Inclusion Approved at January 2017 PGC
Guideline for the prophylaxis and treatment of fungal infections in Haematology patients 1. Introduction PAGL Inclusion Approved at January 2017 PGC Haematology, CHUGGS June 2016 This guideline sets out
More informationAntifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationAmphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate
REVIEW Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate PH Chandrasekar Division of Infectious Diseases, Department
More informationSCIENTIFIC DISCUSSION
London, 14 July 2004 Product name: Cancidas Procedure No. EMEA/H/C/379/II/17 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Noxafil) Reference Number: AZ.CP.PHAR.30 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this
More informationThe Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY
The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY CASPOFUNGIN IN THE EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS: A COMPARISON WITH CONVENTIONAL
More informationEmpiric Antimicrobial Therapy in Cancer Patients *
Haematology and Blood Transfusion Vol. 29 Modem Trends in Human Leukemia VI Edited by Neth, Gallo, Greaves, Janka Springer-Verlag Berlin Heidelberg 1985 Empiric Antimicrobial Therapy in Cancer Patients
More informationHOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS?
HOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS? EORTC IFICG START Look for Help? MORTALITYASSOCIATED WITH INVASIVE ASPERGILLOSIS Lin et al. Clin Infect Dis 2001;32:358 100 % 50 n = 178 0 0 60 120
More informationAmphotericin B Colloidal Dispersion vs. Amphotericin B as Therapy for Invasive Aspergillosis
635 Amphotericin B Colloidal Dispersion vs. Amphotericin B as Therapy for Invasive Aspergillosis Mary H. White, Elias J. Anaissie, Shimon Kusne, John R. Wingard, John W. Hiemenz, Alan Cantor, Marc Gurwith,
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationFebrile neutropenia. Febrile neutropenia. Febrile neutropenia. Febrile neutropenia 1/30/2019. Infection in patients with cancer
Manit Sae-teaw B.Pharm, BCP, BCOP Glad dip in pharmacotherapy Faculty of pharmaceutical sciences Ubon Ratchathani University Fever Oral temperature measurement of 38.3 C (101.0 F) single 38.0 C (100.4
More informationComparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia
Comparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia I. Malik ( National Cancer lnsititute, Karachi ) Shaharyar (, Department of Radiotherapy
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK) ABSTRACT
The Hospital for Sick Children Technology Assessment at SickKids (TASK) ABSTRACT CASPOFUNGIN IN THE EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS: A COMPARISON WITH CONVENTIONAL AND LIPOSOMAL
More informationAntifungal therapy guidelines
Background Invasive fungal infections (IFI) can cause significant morbidity and mortality among patients with haematological malignancies. There is good evidence for the use of antifungal prophylaxis in
More informationSafety and tolerability of caspofungin acetate in the treatment of fungal infections
C.A. Sable B-Y T. Nguyen J.A. Chodakewitz M.J. DiNubile Safety and tolerability of caspofungin acetate in the treatment of fungal infections Key words: caspofungin; echinocandin; esophageal candiasis;
More informationInvasive Pulmonary Aspergillosis in
Infection & Sepsis Symposium Porto, April 1-3, 2009 Invasive Pulmonary Aspergillosis in Non-Immunocompromised Patients Stijn BLOT, PhD General Internal Medicine & Infectious Diseases Ghent University Hospital,
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More informationPrimary prophylaxis of invasive fungal infection in patients with haematological diseases
Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:
More informationanidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd
Scottish Medicines Consortium Re-Submission anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 10 October 2008 The Scottish Medicines Consortium
More informationESCMID Online Lecture Library. by author
How To Best Use Antifungal Agents Cornelia Lass-Flörl Division of Hygiene and Medical Microbiology Innsbruck Medical University ESCMID SUMMER SCHOOL 2012 Epidemiology Diagnosis Roadmap Antifungal drugs
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationCandiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital
Candiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital Introduction Nosocomial bacteriuria or candiduria develops in up to 25%
More informationHepatosplenic Candidiasis in Patients with Acute Leukemia: Incidence and Prognostic Implications
375 Hepatosplenic Candidiasis in Patients with Acute Leukemia: Incidence and Prognostic Implications Veli-Jukka Anttila, Erkki Elonen, Stig Nordling, From the Department of Medicine, Divisions of Hematology
More informationCurrent Options in Antifungal Pharmacotherapy
Current Options in Antifungal Pharmacotherapy John Mohr, Pharm.D., Melissa Johnson, Pharm.D., Travis Cooper, Pharm.D., James S. Lewis, II, Pharm.D., and Luis Ostrosky-Zeichner, M.D. Infections caused by
More informationLondon New Drugs Group APC/DTC Briefing
London New Drugs Group APC/DTC Briefing Posaconazole for invasive fungal infections Contents Background 2 Dosing Information 3 Clinical evidence for treatment of infections 3 Clinical evidence for prophyactic
More informationADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia
16 th Annual Meeting of Saudi Society of Hematology 7 th Pan Arab Hematology Association Congress ADVANCES AND CHALLENGES IN HEMATOLOGY Invasive fungal disease management in febrile neutropenia J.A. Maertens,
More informationAspergillosis in the critically ill patient
Aspergillosis in the critically ill patient José Artur Paiva Director of Emergency and Intensive Care Department Centro Hospitalar São João Porto Associate Professor of Medicine University of Porto Infection
More informationCombination Antifungal Therapy for Invasive Pulmonary Aspergillosis in a Heart Transplant Recipient
case report Combination Antifungal Therapy for Invasive Pulmonary Aspergillosis in a Heart Transplant Recipient Andres Beiras-Fernandez, 1 * Amir K. Bigdeli, 1 * Thomas Nickel, 2 Sebastian Michel, 1 Peter
More informationCombination Antifungal Therapy for Invasive Aspergillosis
MAJOR ARTICLE Combination Antifungal Therapy for Invasive Aspergillosis Kieren A. Marr, 1,2 Michael Boeckh, 1,2 Rachel A. Carter, 1 Hyung Woo Kim, 1 and Lawrence Corey 1,2 1 Fred Hutchinson Cancer Research
More informationOliver A. Cornely. Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2. Centre for Clinical Research
Management of Confirmed Aspergillosis Oliver A. Cornely 1 Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2 Centre for Clinical Research University of Cologne
More informationHistorically, amphotericin B deoxycholate
OUR CURRENT UNDERSTANDING OF THERAPIES FOR INVASIVE FUNGAL INFECTIONS * John R. Perfect, MD ABSTRACT This article provides an update on the current state of the art for treating invasive fungal infections,
More informationEmpirical Antifungal Therapy 2009 Update of ECIL-1 / ECIL-2 Guidelines O. Marchetti, C. Cordonnier, T. Calandra
UPDATE ECIL-3 2009 Empirical Antifungal Therapy 2009 Update of ECIL-1 / ECIL-2 Guidelines O. Marchetti, C. Cordonnier, T. Calandra 1 Background Empirical antifungal therapy for suspected invasive fungal
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vfend) Reference Number: AZ.CP.PHAR.39 Effective Date: 11.16.16 Last Review Date: 09.11.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy
More informationWhen is failure failure?
When is failure failure? Bart-Jan Kullberg, M.D. Radboud University Nijmegen The Netherlands The ICU patient with candidemia!! Female, 39 years old!! Multiple abdominal surgeries for Crohn's disease!!
More informationInvasive aspergillosis (IA) is a leading cause of infectious death in
292 Efficacy and Toxicity of Caspofungin in Combination with Liposomal Amphotericin B as Primary or Salvage Treatment of Invasive Aspergillosis in Patients with Hematologic Malignancies Dimitrios P. Kontoyiannis,
More informationAntifungal prophylaxis in haematology patients: the role of voriconazole
REVIEW 10.1111/j.1469-0691.2012.03772.x Antifungal prophylaxis in haematology patients: the role of voriconazole Y. Hicheri 1, G. Cook 2 and C. Cordonnier 1 1) Service d Hématologie Clinique, Assistance
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON THE CLINICAL EVALUATION OF NEW AGENTS FOR INVASIVE FUNGAL INFECTIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 22 May 2003 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON THE CLINICAL
More informationShannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008
Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes
More informationAntifungal Prophylaxis in Severely Neutropenic Patients: How Much Fluconazole is Necessary?
ORIGINAL ARTICLE Antifungal Prophylaxis in Severely Neutropenic Patients: How Much Fluconazole is Necessary? Christian En Delden', Daniel l? Lew', Bernard Chapuis2, Peter Rohner' and Bernard Hirschel'
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationChallenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
More information